GSK tops third-quarter estimates as new medicines drive growth, keeps outlook

Oct 28 (Reuters) – GSK beat third-quarter sales and profit expectations on Wednesday, helped by demand for new and specialty medicines, suggesting CEO Luke Miels’ efforts to accelerate growth and prepare the company for looming patent expiries are on track. The update comes as Miels steers the British drugmaker through its biggest strategic overhaul in years after taking over at the start of…

Open True Mainstream to compare left, right, and center coverage

1,600+ newsrooms tracked, in English, around the clock. Real newsrooms only — no NGOs, no press releases. Left/Right tags come from reader feedback. No algorithmic feed.